<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pharmjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Разработка и регистрация лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Drug development &amp; registration</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-2066</issn><issn pub-type="epub">2658-5049</issn><publisher><publisher-name>LLC «CPHA»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33380/2305-2066-2025-14-3-2128</article-id><article-id custom-type="elpub" pub-id-type="custom">pharmjournal-2143</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ФАРМАЦЕВТИЧЕСКАЯ ТЕХНОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PHARMACEUTICAL TECHNOLOGY</subject></subj-group></article-categories><title-group><article-title>Выбор полимерного носителя для создания твердой дисперсной системы диосмина методом экструзии горячего расплава</article-title><trans-title-group xml:lang="en"><trans-title>Polymer carrier selection for creation of diosmin solid dispersion system by hot melt extrusion</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0191-7342</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Данилова</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Danilova</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>197022, г. Санкт-Петербург, ул. Профессора Попова, д. 14, литера А</p></bio><bio xml:lang="en"><p>14A, Prof. Popova str., Saint-Petersburg, 197022</p></bio><email xlink:type="simple">shmarova.aleksandra@pharminnotech.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4716-7866</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вишняков</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vishnyakov</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>197022, г. Санкт-Петербург, ул. Профессора Попова, д. 14, литера А</p></bio><bio xml:lang="en"><p>14A, Prof. Popova str., Saint-Petersburg, 197022</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7005-2477</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сурбеева</surname><given-names>Е. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Surbeeva</surname><given-names>E. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>197022, г. Санкт-Петербург, ул. Профессора Попова, д. 14, литера А</p></bio><bio xml:lang="en"><p>14A, Prof. Popova str., Saint-Petersburg, 197022</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1922-3282</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гусев</surname><given-names>К. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Gusev</surname><given-names>K. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>197022, г. Санкт-Петербург, ул. Профессора Попова, д. 14, литера А</p></bio><bio xml:lang="en"><p>14A, Prof. Popova str., Saint-Petersburg, 197022</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8070-1699</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маймистов</surname><given-names>Д. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Maimistov</surname><given-names>D. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>197022, г. Санкт-Петербург, ул. Профессора Попова, д. 14, литера А</p></bio><bio xml:lang="en"><p>14A, Prof. Popova str., Saint-Petersburg, 197022</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8077-2462</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Флисюк</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Flisyuk</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>197022, г. Санкт-Петербург, ул. Профессора Попова, д. 14, литера А</p></bio><bio xml:lang="en"><p>14A, Prof. Popova str., Saint-Petersburg, 197022</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное образовательное учреждение высшего образования «Санкт-Петербургский государственный химико-фармацевтический университет» Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФУ Минздрава России)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Saint-Petersburg State Chemical and Pharmaceutical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>02</day><month>09</month><year>2025</year></pub-date><volume>14</volume><issue>3</issue><fpage>98</fpage><lpage>107</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Данилова А.А., Вишняков Е.В., Сурбеева Е.С., Гусев К.А., Маймистов Д.Н., Флисюк Е.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Данилова А.А., Вишняков Е.В., Сурбеева Е.С., Гусев К.А., Маймистов Д.Н., Флисюк Е.В.</copyright-holder><copyright-holder xml:lang="en">Danilova A.A., Vishnyakov E.V., Surbeeva E.S., Gusev K.A., Maimistov D.N., Flisyuk E.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmjournal.ru/jour/article/view/2143">https://www.pharmjournal.ru/jour/article/view/2143</self-uri><abstract><sec><title>Введение</title><p>Введение. Крайне неудовлетворительные физико-химические и технологические свойства диосмина, входящего в состав ряда востребованных флебопротекторных лекарственных средств, становятся причиной увеличения терапевтической дозировки активного вещества в лекарственной форме и влияют на усложнение производственного процесса. С целью улучшения характеристик активной субстанции предложена технология создания твердых дисперсных систем методом экструзии горячего расплава. Особую значимость в контексте рассматриваемого подхода приобретает выбор эффективной полимерной матрицы.</p></sec><sec><title>Цель</title><p>Цель. Выбор и обоснование использования полимерного носителя из группы поливинилпирролидонов для создания твёрдой дисперсии диосмина методом экструзии горячего расплава.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Объект исследования: субстанция диосмина (субстанция-порошок, Chengdu Runde Pharmaceutical Co., Ltd., Китай). В качестве кандидатов для разработки твердых дисперсий с модельным соотношением АФС и носителя 1 : 99 выбраны два родственных гидрофильных полимера: сополимер поливинилпирролидона с винилацетатом в соотношении 60 : 40 (ПВПВА) марки VIVAPHARM® PVP/VA 64 (JRS PHARMA GmbH &amp; Co. KG, Германия) и поливинилпирролидон марки Kollidon® K17 PF (BASF, США). Термические свойства АФС и полимеров-носителей исследовали с помощью синхронного термического анализа. Получение ТДС диосмина осуществляли с помощью двухшнекового лабораторного экструдера HAAKE™ MiniCTW (Thermo Fisher Scientific, Германия). Количественное содержание диосмина в составе твердых дисперсий определяли методом ВЭЖХ. Для оценки влияния процесса экструзии на функциональные характеристики образцов изучали технологические свойства АФС и измельченных твердых дисперсий. В том числе исследовали термические и структурные характеристики методами дифференциально-сканирующей калориметрии и ИК-Фурье-спектроскопии соответственно.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Использование Kollidon® K17 в составе бинарных твердых дисперсий диосмина является неэффективным по причине повышенной вязкости расплава, наличия рисков образования неоднородной системы, а также потенциального ухудшения технологических свойств образцов относительно исходной микронизированной АФС. С учетом особенностей ведения процесса экструзии, а также принимая во внимание результаты оценки термических, структурных и технологических характеристик твердых дисперсных систем, сделан вывод об эффективности использования сополимера поливинилпирролидона с винилацетатом. Рассматриваемая полимерная матрица позволяет обеспечить более однородное диспергирование и сплавление с диосмином наряду с тенденцией к возможной аморфизации действующего вещества, что позволит в том числе улучшить свойства его растворимости.</p></sec><sec><title>Заключение</title><p>Заключение. Использование сополимера поливинилпирролидона с винилацетатом способствует улучшению неудовлетворительных характеристик микронизированной субстанции диосмина, что в перспективе позволит нивелировать отклонения в ходе процесса производства твердых лекарственных форм за счет снижения рисков пылеобразования, механических потерь в совокупности с обеспечением однородности дозирования.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. The extremely unfavorable physical, chemical and functional properties of diosmin, a component of a number of popular phleboprotective drugs, cause an increased therapeutic dosage of the active pharmaceutical ingredient (API) in the dosage form and complicate the manufacturing process. In order to improve the characteristics of API, a technology of solid dispersion systems (SDS) creation by hot melt extrusion (HME) has been proposed. Particular importance in the context of current approach is attached to the selection of an effective polymer matrix.</p></sec><sec><title>Aim</title><p>Aim. The selection and justification of using a polymer carrier from the polyvinylpyrrolidone group for creating diosmin solid dispersions by hot melt extrusion.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. Object of study: diosmin (powder micronized substance, Chengdu Runde Pharmaceutical Co., Ltd., China). As candidates for the development of solid dispersions with a model ratio of API to carrier of 1 : 99, two related hydrophilic polymers were selected: a copolymer of polyvinylpyrrolidone with vinyl acetate in a ratio of 60 : 40 (PVPVA) – VIVAPHARM® PVP/VA 64 (JRS PHARMA GmbH &amp; Co. KG, Germany), and polyvinylpyrrolidone brand Kollidon® K17 PF (BASF, USA). The thermal properties of the API and polymer carrier were characterized using synchronous thermal analysis. Diosmin SDS were obtained using a HAAKE™ MiniCTW twin-screw extruder (Thermo Fisher Scientific, Germany). The quantitative content of diosmin in the solid dispersions was determined by HPLC. To assess the effect of the extrusion process on the sample characteristics, the functional properties of API and milled SDS were compared. In particular, the thermal and structural characteristics were studied using differential scanning calorimetry and FTIR spectroscopy, respectively.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. Kollidon® K17 is not effective in binary diosmin solid dispersions due to the increased viscosity of the melt, the risk of forming a heterogeneous system, and the potential degradation of the samples' functional properties relative to the pure micronized API. Taking into account the specifics of the extrusion process, as well as the results of the thermal, structural, and functional characteristics analysis of SDS, it was concluded that copolymer of polyvinylpyrrolidone with vinyl acetate is the most effective. This polymer matrix enables more uniform dispersion and fusion with diosmin, along with a tendency towards possible amorphization of the API, and thus – the possibility of solubility properties improvement.</p></sec><sec><title>Conclusion</title><p>Conclusion. The utilization of a copolymer of polyvinylpyrrolidone with vinyl acetate improves the unfavorable characteristics of micronized diosmin, which will eventually eliminate deviations during the manufacturing process of solid dosage forms by reducing the risks of dust formation and mechanical losses, as well as ensuring uniform dosing.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>диосмин</kwd><kwd>ПВПВА 64</kwd><kwd>Kollidon® K17</kwd><kwd>твердые дисперсии</kwd><kwd>экструзия горячего расплава</kwd><kwd>технологические свойства</kwd><kwd>температура стеклования</kwd></kwd-group><kwd-group xml:lang="en"><kwd>diosmin</kwd><kwd>PVPVA 64</kwd><kwd>Kollidon® K17</kwd><kwd>solid dispersion systems</kwd><kwd>hot melt extrusion</kwd><kwd>functional properties</kwd><kwd>glass transition temperature</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена на базе Центра коллективного пользования (ЦКП) «Аналитический центр ФГБОУ ВО СПХФУ Минздрава России».</funding-statement><funding-statement xml:lang="en">The results of the work were obtained with equipment of the Center for Collective Use «Analytical Center of Saint- Petersburg State Chemical and Pharmaceutical University».</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Baylis R. A., Smith N. L., Klarin D., Fukaya E. Epidemiology and genetics of venous thromboembolism and chronic venous disease. Circulation research. 2021;128(12):1988–2002. DOI: 10.1161/CIRCRESAHA.121.318322.</mixed-citation><mixed-citation xml:lang="en">Baylis R. A., Smith N. L., Klarin D., Fukaya E. Epidemiology and genetics of venous thromboembolism and chronic venous disease. Circulation research. 2021;128(12):1988–2002. DOI: 10.1161/CIRCRESAHA.121.318322.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Benn S., Moore Z., Patton D., O'Connor T., Nugent L., Harkin D., Avsar P. What is the prevalence of chronic venous disease among health care workers? A scoping review. Interntional Wound Journal. 2023;20(9):3821–3839. DOI: 10.1111/iwj.14222.</mixed-citation><mixed-citation xml:lang="en">Benn S., Moore Z., Patton D., O'Connor T., Nugent L., Harkin D., Avsar P. What is the prevalence of chronic venous disease among health care workers? A scoping review. Interntional Wound Journal. 2023;20(9):3821–3839. DOI: 10.1111/iwj.14222.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ortega M. A., Fraile-Martínez O., García-Montero C., Álvarez-Mon M. A., Chaowen C., Ruiz-Grande F., Pekarek L., Monserrat J., Asúnsolo A., García-Honduvilla N., Álvarez-Mon M., Bujan J. Understanding chronic venous disease: a critical overview of its pathophysiology and medical management. Journal of Clinical Medicine. 2021;10(15):3239. DOI: 10.3390/jcm10153239.</mixed-citation><mixed-citation xml:lang="en">Ortega M. A., Fraile-Martínez O., García-Montero C., Álvarez-Mon M. A., Chaowen C., Ruiz-Grande F., Pekarek L., Monserrat J., Asúnsolo A., García-Honduvilla N., Álvarez-Mon M., Bujan J. Understanding chronic venous disease: a critical overview of its pathophysiology and medical  management.  Journal of Clinical Medicine. 2021;10(15):3239. DOI: 10.3390/jcm10153239.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">De Maessener M. G., Kakkos S. K., Aherne T., Baekgaard N., Black S., Blomgren L., Giannoukas A., Gohel M., de Graaf R., Hamel-Desnos C., Jawien A., Jaworucka-Kaczorowska A., Lattimer C. R., Mosti G., Noppeney T., van Rijn M. J., Stansby G., Kolh P., Bastos Goncalves F., Chakfé N., Coscas R., de Borst G. J., Dias N. V., Hinchliffe R. J., Koncar I. B., Lindholt J. S., Trimarchi S., Tulamo R., Twine C. P., Vermassen F., Wanhainen A., Björck M., Labropoulos N., Lurie F., Mansilha A., Nyamekye I. K., Ramirez Ortega M., Ulloa J. H., Urbanek T., van Rij A. M., Vuylsteke M. E. Editor's Choice – European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the management of chronic venous disease of the lower limbs. European Journal of Vascular and Endovascular Surgery. 2022;63(2):184–267. DOI: 10.1016/j.ejvs.2021.12.024.</mixed-citation><mixed-citation xml:lang="en">De Maessener M. G., Kakkos S. K., Aherne T., Baekgaard N., Black S., Blomgren L., Giannoukas A., Gohel M., de Graaf R., Hamel-Desnos C., Jawien A., Jaworucka-Kaczorowska A., Lattimer C. R., Mosti G., Noppeney T., van Rijn M. J., Stansby G., Kolh P., Bastos Goncalves F., Chakfé N., Coscas R., de Borst G. J., Dias N. V., Hinchliffe R. J., Koncar I. B., Lindholt J. S., Trimarchi S., Tulamo R., Twine C. P., Vermassen F., Wanhainen A., Björck M., Labropoulos N., Lurie F., Mansilha A., Nyamekye I. K., Ramirez Ortega M., Ulloa J. H., Urbanek T., van Rij A. M., Vuylsteke M. E. Editor's Choice – European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the management of chronic venous disease of the lower limbs. European Journal of Vascular and Endovascular Surgery. 2022;63(2):184–267. DOI: 10.1016/j.ejvs.2021.12.024.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Головина В. И., Золотухин И. А. Применение диосминсодержащих препаратов в лечении хронических заболеваний вен. Лечебное дело. 2023;2:67–73. DOI: 10.24412/2071-5315-2023-12881.</mixed-citation><mixed-citation xml:lang="en">Golovina V. I., Zolotukhin I. А. The Use of Diosmin Drugs in the Treatment of Chronic Venous Insufficiency. Medical practice. 2023;2:67–73. (In Russ.) DOI: 10.24412/2071-5315-2023-12881.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Gerges S. H., Wahdan S. A., Elsherbiny D. A., El-Demerdash E. Pharmacology of Diosmin, a Citrus Flavone Glycoside: An Updated Review. European Journal of Drug Metabolism and Pharmacokinetics. 2022;47:1–18. DOI: 10.1007/s13318-021-00731-y.</mixed-citation><mixed-citation xml:lang="en">Gerges S. H., Wahdan S. A., Elsherbiny D. A., El-Demerdash E. Pharmacology of Diosmin, a Citrus Flavone Glycoside: An Updated Review. European Journal of Drug Metabolism and Pharmacokinetics. 2022;47:1–18. DOI: 10.1007/s13318-021-00731-y.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Богачев В. Ю., Болдин Б. В., Комов К. В., Дженина О. В. Фиксированные комбинации в фармакотерапии хронических заболеваний вен. Амбулаторная хирургия. 2024;21(2):44–51. DOI: 10.21518/akh2024-042.</mixed-citation><mixed-citation xml:lang="en">Bogachev V. Y., Boldin B. V., Komov K. V., Dzhenina O. V. Fixed-dose combinations in pharmacotherapy of chronic venous diseases. Ambulatory Surgery. 2024;21(2):44–51. (In Russ.) DOI:10.21518/akh2024-042.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lurie F., Branisteanu D. E. Improving Chronic Venous Disease Management with Micronised Purified Flavonoid Fraction: New Evidence from Clinical Trials to Real Life. Clinical Drug Investigation. 2023;43(1):9–13. DOI: 10.1007/s40261-023-01261-y.</mixed-citation><mixed-citation xml:lang="en">Lurie F., Branisteanu D. E. Improving Chronic Venous Disease Management with Micronised Purified Flavonoid Fraction: New Evidence from Clinical Trials to Real Life. Clinical Drug Investigation. 2023;43(1):9–13. DOI: 10.1007/s40261-023-01261-y.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Данилова А. А., Гусев К. А., Маймистов Д. Н., Флисюк Е. В. Технология экструзии горячего расплава как современная стратегия улучшения биодоступности флавоноидов. Химико-фармацевтический журнал. 2024;58(2):26–35. DOI: 10.30906/0023-1134-2024-58-2-26-35.</mixed-citation><mixed-citation xml:lang="en">Danilova А. А., Gusev K. A., Maimistov D. N., Flisyuk E. V. Hot Melt Extrusion Technology as a Modern Strategy for Improving the Bioavailability of Flavonoids. Chemical and Pharmaceutical Journal. 2024;58(2):26–35. (In Russ.) DOI: 10.30906/0023-1134-2024-58-2-26-35.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Tong M., Wu X., Zhang S., Hua D., Li S., Yu X., Wang J., Zhang Z. Application of TPGS as an efflux inhibitor and a plasticizer in baicalein solid dispersion. European Journal of Pharmaceutical Sciences. 2022;168:106071. DOI: 10.1016/j.ejps.2021.106071.</mixed-citation><mixed-citation xml:lang="en">Tong M., Wu X., Zhang S., Hua D., Li S., Yu X., Wang J., Zhang Z. Application of TPGS as an efflux inhibitor and a plasticizer in baicalein solid dispersion. European Journal of Pharmaceutical Sciences. 2022;168:106071. DOI: 10.1016/j.ejps.2021.106071.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Wdowiak K., Pietrzak R., Tykarska E., Cielecka-Piontek J. Hot-Melt Extrusion as an Effective Technique for Obtaining an Amorphous System of Curcumin and Piperine with Improved Properties Essential for Their Better Biological Activities. Molecules. 2023;28(9):3848. DOI: 10.3390/molecules28093848.</mixed-citation><mixed-citation xml:lang="en">Wdowiak K., Pietrzak R., Tykarska E., Cielecka-Piontek J. Hot-Melt Extrusion as an Effective Technique for Obtaining an Amorphous System of Curcumin and Piperine with Improved Properties Essential for Their Better Biological Activities. Molecules. 2023;28(9):3848. DOI: 10.3390/molecules28093848.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Данилова А. А., Гусев К. А., Архипова Н. О., Данилов Л. Г., Вишняков Е. В., Маймистов Д. Н., Флисюк Е. В. Оценка влияния поливинилпирролидон-винилацетата на свойства кверцетина в составе бинарной твердой дисперсии, полученной методом экструзии горячего расплава. Разработка и регистрация лекарственных средств. 2025;14(1):127–137. DOI: 10.33380/2305-2066-2025-14-1-1935.</mixed-citation><mixed-citation xml:lang="en">Danilova A. A., Gusev K. A., Arkhipova N. O., Danilov L. G., Vishnyakov E. V., Maimistov D. N., Flisyuk E. V. Assessment of polyvinylpyrrolidone vinyl acetate effect on quercetin properties in binary solid dispersion prepared by hot melt extrussion. Drug development &amp; registration. 2025;14(1):127–137. (In Russ.) DOI: 10.33380/2305-2066-2025-14-1-1935.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">LaFountaine J. S., Prasad L. K., Brough C., Miller D. A., McGinity J. W., Williams R. O. Thermal Processing of PVP- and HPMC-Based Amorphous Solid Dispersions. AAPS PharmSciTech. 2016;17:120–132. DOI: 10.1208/s12249-015-0417-7.</mixed-citation><mixed-citation xml:lang="en">LaFountaine J. S., Prasad L. K., Brough C., Miller D. A., McGinity J. W., Williams R. O. Thermal Processing of PVP- and HPMC-Based Amorphous Solid Dispersions. AAPS PharmSciTech. 2016;17:120–132. DOI: 10.1208/s12249-015-0417-7.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Гусев К. А., Алиев А. Р., Генералова Ю. Э., Аксенова Н. А., Речкалов Г. В., Маймистов Д. Н., Алексеева Г. М., Флисюк Е. В. Разработка состава и технологии получения аморфной твердой дисперсной системы эбастина методом экструзии горячего расплава для увеличения скорости растворения. Разработка и регистрация лекарственных средств. 2023;12(4):126–135. DOI: 10.33380/2305-2066-2023-12-4-1577.</mixed-citation><mixed-citation xml:lang="en">Gusev K. A., Aliev A. R., Generalova Yu. E., Aksenova N. A., Rechkalov G. V., Maimistov D. N., Alekseeva G. M., Flisyuk E. V. Composition and Technology Development for Obtaining Amorphous Solid Dispersion of Ebastine by Hot Melt Extrusion to Increase Dissolution Rate. Drug development &amp; registration. 2023;12(4):126–135. (In Russ.) DOI: 10.33380/2305-2066-2023-12-4-1577.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Hemalatha G., Sreedevi A., Sruthi K. S., Swetha P. Development and optimization of a simple, robust RP-HPLC technique for analysis of diosmin and hesperidin using quality by design. Journal of Applied Pharmaceutical Science. 2024;14(3):95–101. DOI: 10.7324/JAPS.2024.162037.</mixed-citation><mixed-citation xml:lang="en">Hemalatha G., Sreedevi A., Sruthi K. S., Swetha P. Development and optimization of a simple, robust RP-HPLC technique for analysis of diosmin and hesperidin using quality by design. Journal of Applied Pharmaceutical Science. 2024;14(3):95–101. DOI: 10.7324/JAPS.2024.162037.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Mathers A., Pechar M., Hassouna F., Fulem M. API solubility in semi-crystalline polymer: Kinetic and thermodynamic phase behavior of PVA-based solid dispersions. International Journal of Pharmaceutics. 2022;623:121855. DOI: 10.1016/j.ijpharm.2022.121855.</mixed-citation><mixed-citation xml:lang="en">Mathers A., Pechar M., Hassouna F., Fulem M. API solubility in semi-crystalline polymer: Kinetic and thermodynamic phase behavior of PVA-based solid dispersions. International Journal of Pharmaceutics. 2022;623:121855. DOI: 10.1016/j.ijpharm.2022.121855.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Bühler V. Polyvinylpyrrolidone Excipients for Pharmaceuticals: Povidone, Crospovidone and Copovidone. Berlin: Springer; 2005. 254 c.</mixed-citation><mixed-citation xml:lang="en">Bühler V. Polyvinylpyrrolidone Excipients for Pharmaceuticals: Povidone, Crospovidone and Copovidone. Berlin: Springer; 2005. 254 c.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Browne E., Worku Z. A., Healy A. M. Physicochemical Properties of Poly-Vinyl Polymers and Their Influence on Ketoprofen Amorphous Solid Dispersion Performance: A Polymer Selection Case Study. Pharmaceutics. 2020;12(5):433. DOI: 10.3390/pharmaceutics12050433.</mixed-citation><mixed-citation xml:lang="en">Browne E., Worku Z. A., Healy A. M. Physicochemical Properties of Poly-Vinyl Polymers and Their Influence on Ketoprofen Amorphous Solid Dispersion Performance: A Polymer Selection Case Study. Pharmaceutics. 2020;12(5):433. DOI: 10.3390/pharmaceutics12050433.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Kapourani A., Vardaka E., Katopodis K., Kachrimanis K., Barmpalexis P. Crystallization tendency of APIs possessing different thermal and glass related properties in amorphous solid dispersions. International Journal of Pharmaceutics. 2020;579:119149. DOI: 10.1016/j.ijpharm.2020.119149.</mixed-citation><mixed-citation xml:lang="en">Kapourani A., Vardaka E., Katopodis K., Kachrimanis K., Barmpalexis P. Crystallization tendency of APIs possessing different thermal and glass related properties in amorphous solid dispersions. International Journal of Pharmaceutics. 2020;579:119149. DOI: 10.1016/j.ijpharm.2020.119149.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Kanaze F. I., Kokkalou E., Niopas I., Georgarakis M., Stergiou A., Bikiaris D. Thermal analysis study of flavonoid solid dispersions having enhanced solubility. Journal of thermal analysis and calorimetry. 2006;83(2):283–290. DOI: 10.1007/s10973-005-6989-9.</mixed-citation><mixed-citation xml:lang="en">Kanaze F. I., Kokkalou E., Niopas I., Georgarakis M., Stergiou A., Bikiaris D. Thermal analysis study of flavonoid solid dispersions having enhanced solubility. Journal of thermal analysis and calorimetry. 2006;83(2):283–290. DOI: 10.1007/s10973-005-6989-9.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Hess F., Kipping T., Weitschies W., Krause J. Understanding the Interaction of Thermal, Rheological, and Mechanical Parameters Critical for the Processability of Polyvinyl Alcohol-Based Systems during Hot Melt Extrusion. Pharmaceutics. 2024;16:472. DOI: 10.3390/pharmaceutics16040472.</mixed-citation><mixed-citation xml:lang="en">Hess F., Kipping T., Weitschies W., Krause J. Understanding the Interaction of Thermal, Rheological, and Mechanical Parameters Critical for the Processability of Polyvinyl Alcohol-Based Systems during Hot Melt Extrusion. Pharmaceutics. 2024;16:472. DOI: 10.3390/pharmaceutics16040472.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
